N+1 Singer Reaffirms “Buy” Rating for Puretech Health PLC (PRTC)
PRTC has been the subject of several other reports. Jefferies Group LLC reaffirmed a buy rating and set a GBX 255 ($3.30) target price on shares of Puretech Health PLC in a report on Friday, June 9th. Peel Hunt reaffirmed a buy rating and set a GBX 259 ($3.35) target price on shares of Puretech Health PLC in a report on Wednesday, May 10th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 248 ($3.21) target price on shares of Puretech Health PLC in a report on Wednesday, May 10th. Five research analysts have rated the stock with a buy rating, Puretech Health PLC presently has an average rating of Buy and an average target price of GBX 246.80 ($3.19).
Puretech Health PLC (LON:PRTC) opened at 137.50 on Wednesday. Puretech Health PLC has a 52 week low of GBX 110.00 and a 52 week high of GBX 170.00. The company has a 50-day moving average of GBX 133.48 and a 200 day moving average of GBX 121.39. The firm’s market cap is GBX 319.98 million.
COPYRIGHT VIOLATION WARNING: “N+1 Singer Reaffirms “Buy” Rating for Puretech Health PLC (PRTC)” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/n1-singer-reaffirms-buy-rating-for-puretech-health-plc-prtc/1537869.html.
About Puretech Health PLC
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.